Endocrine therapy for growth retardation in paediatric inflammatory bowel disease

Altowati, M.A., Russell, R.K. and Ahmed, S.F. (2014) Endocrine therapy for growth retardation in paediatric inflammatory bowel disease. Pediatric Drugs, 16(1), pp. 29-42. (doi: 10.1007/s40272-013-0046-0)

Full text not currently available from Enlighten.


Inflammatory bowel disease, particularly Crohn’s disease (CD), can potentially cause growth failure during childhood as well as a reduction in final adult height. The underlying mechanism is multifactorial and includes poor nutrition, chronic inflammation, and the prolonged use of steroids. Despite major advances in the treatment of CD, current cohorts of children continue to display a deficit in linear growth and may qualify for growth-promoting hormonal therapy. However, currently there is limited evidence to support the use of endocrine therapy directed primarily at improving growth. This review is aimed at summarising the current evidence for growth impairment in inflammatory bowel disease and discusses the rationale for using growth promoting therapy.

Item Type:Articles
Glasgow Author(s) Enlighten ID:Russell, Dr Richard and Ahmed, Professor Syed Faisal
Authors: Altowati, M.A., Russell, R.K., and Ahmed, S.F.
College/School:College of Medical Veterinary and Life Sciences > School of Medicine, Dentistry & Nursing
Journal Name:Pediatric Drugs
ISSN (Online):1179-2019

University Staff: Request a correction | Enlighten Editors: Update this record